Evaluation at 3  years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study.

CONCLUSIONS: Concurrent bevacizumab with locoregional radiotherapy is associated with acceptable 3-years toxicity in patients with breast cancer.
PMID: 29650388 [PubMed - as supplied by publisher]

Source: Cancer Radiotherapie - April 9, 2018 Category: Cancer & Oncology Authors: Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, de la Lande B, Baumann P, Missohou F, Lévy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Pernin V, Kirova Y Tags: Cancer Radiother Source Type: research